Label expansions in 2024 created new reimbursement pathways, leading to sharp increases in GLP1 use among Medicare patients, a population historically excluded from weightloss coverage
Among them, weight loss was the most in the double treatment
A greater share 51% of those with preexisting conditions said they abstain from alcohol
23 The recent wave of state Medicaid agencies withdrawing or restricting coverage for AOMs, particularly GLP-1s, reflects a unique tension between groundbreaking clinical efficacy, rapid uptake, optional coverage, and immediate fiscal reality
At this level, you may also qualify for bariatric surgery referrals, though many patients prefer trying GLP-1 therapy first
However, this inhibitory effect is significantly weakened in patients with T2DM, indicating that its potential application in diabetes treatment requires further investigation